以猪脊髓前角运动神经细胞制备的匀浆免疫Balb/c小鼠。按常规方法制备、筛选抗运动神经元单克隆抗体(Monoclonal Antibodies Against moto-neurons McAb)。总计35株杂交瘤细胞所分泌的McAb,与大鼠半月神经节细胞免疫组化反应均呈阴性,3...以猪脊髓前角运动神经细胞制备的匀浆免疫Balb/c小鼠。按常规方法制备、筛选抗运动神经元单克隆抗体(Monoclonal Antibodies Against moto-neurons McAb)。总计35株杂交瘤细胞所分泌的McAb,与大鼠半月神经节细胞免疫组化反应均呈阴性,30株与脊髓前角运动细胞(Mn)呈阳性反应、其中5株McAbs免疫组化反应特异性较强,用ELISA方法测定其滴度在2048~4096之间,免疫双扩散法测定,5株杂交瘤均分泌IgG、展开更多
Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We t...Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375 mg/m2). In this uncontrolled, unblinded trial of rituximab, three patients improved ≥ 1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.展开更多
文摘以猪脊髓前角运动神经细胞制备的匀浆免疫Balb/c小鼠。按常规方法制备、筛选抗运动神经元单克隆抗体(Monoclonal Antibodies Against moto-neurons McAb)。总计35株杂交瘤细胞所分泌的McAb,与大鼠半月神经节细胞免疫组化反应均呈阴性,30株与脊髓前角运动细胞(Mn)呈阳性反应、其中5株McAbs免疫组化反应特异性较强,用ELISA方法测定其滴度在2048~4096之间,免疫双扩散法测定,5株杂交瘤均分泌IgG、
文摘Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375 mg/m2). In this uncontrolled, unblinded trial of rituximab, three patients improved ≥ 1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.